No abstract

Grade of recommendation b (wording associated with the grade of recommendation) Strong"Must," "should," or "ILTS recommends" Weak Can," "may," or "ILTS suggestsAccording to Guyatt GH et al. 32 a Level was downgraded if there was poor quality, strong bias or inconsistency between studies; level was upgraded if there was a large effect size.bRecommendations were reached by consensus of the panel and included the quality of evidence, presumed patient-important outcomes and costs.

Static cold storage Extended hypotermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 h Dynamic preservation with DHOPE Reperfusion and viability assessment 2 h SCS 2 h DHOPE 4 h reperfusion 2 h SCS 6 h DHOPE 4 h reperfusion 2 h SCS 24 h DHOPE 4 h reperfusion 8-11 h SCS 20 h DHOPE 3 h reperfusion 24 h SCS 4 h reperfusion Decreasing venous and arterial flows, no bile production, injured appearence Non-viable livers • Lactate clearance, blood pH, glucose, ALT • Biliary pH, bicarbonate, LDH • HMGB-1, IL-6, TNFα, cfDNA • Bile duct and liver parenchyma histology Viable livers, all with similar: Lactate <1.7 mmol/L, perfusate pH7.35-7.45, bile production >10 ml, biliary pH >7.45 Livers meet viability criteria during 2.5 h Highlights DHOPE can be extended for up to 24 h to prolong donor liver preservation time. Hepatocellular and biliary function is maintained after ex situ preservation by 24 h DHOPE. Extension of DHOPE for up to 24 h does not induce more injury compared to shorter preservation times. The initial results of extended preservation by DHOPE for discarded human livers are promising. Lay summary It has been suggested that preserving liver grafts with a technique called (dual) hypothermic oxygenated machine perfusion ([D]HOPE) leads to better outcomes after transplantation than if livers are stored on ice, especially if an organ is of lesser quality. In this study, we showed that DHOPE could be used to preserve liver grafts for up to 24 h. This extended procedure could be used globally to facilitate transplantation and expand the donor pool.

The transplant community continues to be challenged by the disparity between the need for liver transplantation and the shortage of suitable donor organs. At the same time, the number of unused donor livers continues to increase, most likely attributed to the worsening quality of these organs. To date, there is no reliable marker of liver graft viability that can predict good posttransplant outcomes. Ex situ machine perfusion offers additional data to assess the viability of donor livers before transplantation. Hence, livers initially considered unsuitable for transplantation can be assessed during machine perfusion in terms of appearance and consistency, hemodynamics, and metabolic and excretory function. In addition, postoperative complications such as primary nonfunction or posttransplant cholangiopathy may be predicted and avoided. A variety of viability criteria have been used in machine perfusion, and to date there is no widely accepted composition of criteria for clinical use. This review discusses potential viability markers for hepatobiliary function during machine perfusion, describes current limitations, and provides future recommendations for the use of viability criteria in clinical liver transplantation.

Because of the high demand of organs, the usage of marginal grafts has increased. These marginal organs have a higher risk of developing ischemia-reperfusion injury, which can lead to posttransplant complications. Ex situ machine perfusion (MP), compared with the traditional static cold storage, may better protect these organs from ischemia-reperfusion injury. In addition, MP can also act as a platform for dynamic administration of pharmacological agents or gene therapy to further improve transplant outcomes. Numerous therapeutic agents have been studied under both hypothermic (1–8°C) and normothermic settings. Here, we review all the therapeutics used during MP in different organ systems (lung, liver, kidney, heart). The major categories of therapeutic agents include vasodilators, mesenchymal stem cells, antiinflammatory agents, antiinfection agents, siRNA, and defatting agents. Numerous animal and clinical studies have examined MP therapeutic agents, some of which have even led to the successful reconditioning of discarded grafts. More clinical studies, especially randomized controlled trials, will need to be conducted in the future to solidify these promising results and to define the role of MP therapeutic agents in solid organ transplantation.